Compile Data Set for Download or QSAR
Report error Found 3253 Enz. Inhib. hit(s) with Target = 'Cathepsin K'
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19736(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-[2-(4-meth...)
Affinity DataIC50: 0.00300nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19737(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-[2-(3-meth...)
Affinity DataIC50: 0.00300nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167296((1S)-2-cyclohexyl-1-methylethyl 2-cyano-2-ethylhyd...)
Affinity DataKi:  0.00300nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19743(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-(2-{4-[2-(...)
Affinity DataIC50: 0.00300nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19744(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-(2-{3-[2-(...)
Affinity DataIC50: 0.00300nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167302((1S)-2-cyclohexyl-1-methylethyl 2-cyano-2-isobutyl...)
Affinity DataKi:  0.00400nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167295((1S)-2-cyclohexyl-1-methylethyl 2-cyano-2-propylhy...)
Affinity DataKi:  0.00400nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50098576(5-(2-MORPHOLIN-4-YLETHOXY)BENZOFURAN-2-CARBOXYLIC ...)
Affinity DataKi:  0.00480nMAssay Description:Inhibition of Human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Rabbit)
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19518(CHEMBL195454 | (2S)-N-(cyanomethyl)-4-methyl-2-{[(...)
Affinity DataIC50: 0.00500nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2007
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167298((1S)-2-cyclohexyl-1-methylethyl 2-benzyl-2-cyanohy...)
Affinity DataKi:  0.00600nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167303((1S)-2-cyclohexyl-1-methylethyl 2-butyl-2-cyanohyd...)
Affinity DataKi:  0.00700nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19733(2-cyano-4-(cyclohexylamino)-N-[2-(3-methoxyphenyl)...)
Affinity DataIC50: 0.00900nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167289((1S)-2-cyclohexyl-1-methylethyl 2-cyano-2-methylhy...)
Affinity DataKi:  0.00900nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19770((2S)-2-(1-benzofuran-2-ylformamido)-4-methyl-N-[(4...)
Affinity DataKi:  0.00990nM ΔG°:  -62.2kJ/molepH: 5.5 T: 2°CAssay Description:Potential inhibitors were evaluated using the progress curve method. Assays were carried out in the presence of variable concentrations of test compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19731(2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrim...)
Affinity DataIC50: 0.0100nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19740(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-{2-[3-(4-m...)
Affinity DataIC50: 0.0110nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19741(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-(2-{4-[(4-...)
Affinity DataIC50: 0.0110nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335280(N-(Benzylcarbamoyl)-leucyl-methylazaalanine-nitril...)
Affinity DataKi:  0.0110nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19742(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-(2-{4-[(1-...)
Affinity DataIC50: 0.0130nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50251429(4'-Piperazin-1-yl-biphenyl-4-carboxylic acid [(S)-...)
Affinity DataIC50: 0.0150nMAssay Description:Inhibition of cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2010
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335281(N-(Phenylcarbamoyl)-leucyl-methylazaalanine-nitril...)
Affinity DataKi:  0.0170nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167290((1S)-2-cyclohexyl-1-methylethyl 2-cyano-2-isopropy...)
Affinity DataKi:  0.0190nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19732(2-cyano-4-(cyclohexylamino)-N-[2-(4-methoxyphenyl)...)
Affinity DataIC50: 0.0220nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335285(N-{4-[5-(2-Thienyl)-1,2,4-oxadiazol-3-yl]phenylcar...)
Affinity DataKi:  0.0220nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19739(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-{2-[4-(4-m...)
Affinity DataIC50: 0.0250nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50169493((S)-3,3-dimethyl-1-(4-(4-(trifluoromethyl)phenyl)-...)
Affinity DataIC50: 0.0251nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50169495([(S)-1-(2H-Pyrazol-3-ylaminooxalyl)-pentyl]-carbam...)
Affinity DataIC50: 0.0257nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50169482([(S)-1-(2H-Pyrazol-3-ylaminooxalyl)-pentyl]-carbam...)
Affinity DataIC50: 0.0288nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19745(2-cyano-4-[(2,2-dimethylpropyl)amino]-N-(2-{3-[2-(...)
Affinity DataIC50: 0.0310nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335289(N-{4-[5-(2-Thienyl)-1,2,4-oxadiazol-3-yl]benzoyl}-...)
Affinity DataKi:  0.0320nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50167288((1S)-1-benzylpropyl 2-cyano-2-methylhydrazinecarbo...)
Affinity DataKi:  0.0320nMAssay Description:Inhibition constant against human cathepsin K in fluorescence assay using Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19778((2S)-2-(1-benzofuran-2-ylformamido)-4-methyl-N-[(4...)
Affinity DataKi:  0.0410nM ΔG°:  -58.7kJ/molepH: 5.5 T: 2°CAssay Description:Potential inhibitors were evaluated using the progress curve method. Assays were carried out in the presence of variable concentrations of test compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335284(N-[4-(5-Methyl-1,2,4-oxadiazol-3-yl)phenylcarbamoy...)
Affinity DataKi:  0.0450nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19735(2-cyano-4-(cyclohexylamino)-N-{2-[4-(4-methylpiper...)
Affinity DataIC50: 0.0470nMpH: 7.0 T: 2°CAssay Description:The substrate hydrolysis with or without inhibitor was monitored at an excitation wavelength of 360nm and an emission wavelength of 460 nm on a fluor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50163831((2S)-1-cyclohexylpropan-2-yl 1-cyanoazetidine-2-ca...)
Affinity DataIC50: 0.0480nMAssay Description:Inhibitory concentration against human cathepsin K using 10 uM Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50304794((S)-benzyl 1-(2-cyano-1,2-dimethylhydrazinyl)-4-me...)
Affinity DataKi:  0.0640nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335278(N-(Benzyloxycarbonyl)-cyclohexylalanyl-methylazala...)
Affinity DataKi:  0.0710nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Rat)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50167288((1S)-1-benzylpropyl 2-cyano-2-methylhydrazinecarbo...)
Affinity DataKi:  0.0720nMAssay Description:Inhibition constant against rat cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19783((2S)-3,3-dimethyl-1-{3-[4-(trifluoromethyl)phenyl]...)
Affinity DataIC50: 0.0720nMpH: 5.5 T: 2°CAssay Description:Assays were carried out in the presence of variable concentrations of test compound. Reactions were initiated by addition of enzyme to buffered solut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2008
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335283(N-{4-[5-(2-Thienyl)-1,2,4-oxadiazol-3-yl]benzylcar...)
Affinity DataKi:  0.0720nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM19783((2S)-3,3-dimethyl-1-{3-[4-(trifluoromethyl)phenyl]...)
Affinity DataIC50: 0.0724nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetCathepsin K(Rabbit)
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19908((1R,2R)-N-(cyanomethyl)-5,5-difluoro-2-{2-methyl-4...)
Affinity DataIC50: 0.100nM EC50:  17nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2008
Entry Details Article
PubMed
TargetCathepsin K(Rabbit)
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19530((2S)-N-(cyanomethyl)-4-methyl-2-{[(1S)-2,2,2-trifl...)
Affinity DataIC50: 0.100nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2007
Entry Details Article
PubMed
TargetCathepsin K(Rabbit)
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19524((2S)-N-(cyanomethyl)-4-methyl-2-{[(1S)-2,2,2-trifl...)
Affinity DataIC50: 0.100nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2007
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50084655([(S)-1-((S)-1-Formyl-pentylcarbamoyl)-3-methyl-but...)
Affinity DataIC50: 0.110nMAssay Description:Inhibitory activity against human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50084655([(S)-1-((S)-1-Formyl-pentylcarbamoyl)-3-methyl-but...)
Affinity DataIC50: 0.110nMAssay Description:Inhibitory activity against recombinant human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50461260(CHEMBL4228926)
Affinity DataIC50: 0.110nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50335282(N-[4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzylcarbamoy...)
Affinity DataKi:  0.110nMAssay Description:Inhibition of human recombinant cathepsin K after 30 mins by spectrophotometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/4/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50169488((1R)-2,2-DIMETHYL-1-({5-[4-(TRIFLUOROMETHYL)PHENYL...)
Affinity DataIC50: 0.129nMAssay Description:Inhibition of human cathepsin KMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetCathepsin K(Human)
Novartis Pharmaceuticals

LigandPNGBDBM50148310(((S)-1-Formyl-pentyl)-carbamic acid (S)-1-benzyl-p...)
Affinity DataIC50: 0.130nMAssay Description:Inhibitory concentration against human cathepsin K using 10 uM Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Displayed 1 to 50 (of 3253 total ) | Next | Last >>
Jump to: